Asset profile
survodutide
Peptide
Evidence outlook · lead readout
SYNCHRONIZE-1 (NCT06066515) · Obesity
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
SYNCHRONIZE-1 (NCT06066515): In this randomized, double-blind, placebo-controlled Phase 3 trial in 726 adults with obesity, survodutide produced substantially greater weight loss than placebo at 76 weeks (average 16.6% body weight reduction vs 3.2% with placebo, a highly significant difference).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Type 2 Diabetes · Phase 3MASH / NASH · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
144 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 138 same-indication; 40 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Survodutide: this drug | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| AZD9550 | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | ||
| PB-718 | Phase 1/2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| DA-1726 | Phase 1 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) |
…and 129 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
2027 (4)
January 2027 (3)
What to watch
What to watch
What to watch
November 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
2029 (2)
2031 (1)
December 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.